PDCD1 and nasopharyngeal carcinoma: Recently, results of two-phase 3 clinical trials showed that anti-PD-1 antibodies plus gemcitabine-cisplatin chemotherapy as first-line treatment in advanced NPC patients had superior PFS compared to chemotherapy alone, and this regimen could be a new standard of care for metastatic or recurrent NPC (57, 58).